Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 9/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | DRD3 | P35462 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18687288 | 0.85 | CD38 (0.34) | CD38EPHX2 | |
| SCHEMBL18687467 | 0.85 | CD38 (0.34) | CD38EPHX2 | |
| SCHEMBL4805338 | 0.79 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL4805368 | 0.79 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL22764075 | 0.79 | SMYD3 (0.34) | CD38 | |
| SCHEMBL22764118 | 0.79 | SMYD3 (0.34) | CD38 | |
| SCHEMBL12200376 | 0.78 | NPC1 (0.34) | CD38 | |
| SCHEMBL13652632 | 0.78 | — | — | |
| SCHEMBL18687289 | 0.77 | CD38 (0.36) | CD38EPHX2 | |
| SCHEMBL1678882 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385369-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | GB005 INC (US) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385369-A1 | NEW BENZIMIDAZOLES DERIVATIVES AS TEC KINASES FAMILY INHIBITORS | BMX, TEC, BTK | CD38 2840/4885CYP1A2 3658/4885CYP2D6 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.